Telacebec (Q203)

Qurient Co., Ltd, Qurient Co. Ltd. / LLC "Infectex", a portfolio firm of Maxwell Biotech Venture Fund
Telacebec, IAP6, CAS No. 1334719-95-7
Chemical Class:
Imidazopyridine amide

February 2022. Publication. Hards, Kiel et al. “An amiloride derivative is active against the F1Fo-ATP synthase and cytochrome bd oxidase of Mycobacterium tuberculosis.” Communications Biology vol. 5,1 166. PMCID: PMC8873251

January 2021. Publication. Lee, Bei Shi et al. “Dual inhibition of the terminal oxidases eradicates antibiotic-tolerant Mycobacterium tuberculosis.” EMBO Molecular Medicine vol. 13,1 (2021): e13207. PMCID: PMC7799364

March 26, 2020.  Publication. de Jager, Veronique R et al. “Telacebec (Q203), a New Antituberculosis Agent.” The New England Journal of Medicine vol. 382,13 (2020): 1280-1281.

June 3, 2019.  Qurient press release:  SEONGNAM-SI, South Korea--(BUSINESS WIRE)-- Qurient Co. Ltd. today announced positive results from the Phase 2a EBA (early bactericidal activity) clinical trial for telacebec (Q203), a first-in-class, orally-available antibiotic for the treatment of tuberculosis (TB). Telacebec is a selective inhibitor with high specificity for the cytochrome bc1 complex of Mycobacterium tuberculosis. This complex is a critical component of the electron transport chain, and inhibition disrupts the bacterium’s ability to generate energy.

The EBA trial assessed the pharmacokinetics, safety, and activity of telacebec in three dose strength (100 mg, 200 mg and 300 mg) in the treatment of adult patients with pulmonary TB. Telacebec met the primary objective of rate of change in the time to positivity (TTP) in sputum over days 0 to 14. Telacebec was safe and well tolerated throughout the different dose strengths. Full results from EBA trial are expected to be presented at future scientific meetings.

Phase 2. EBA began July 2018 in South Africa and concluded September 9, 2019.

June 2018. Q203 has a non-proprietary name assigned: telacebec. USAN: -cebec Cytochrome bc1 complex inhibitors in Mycobacterium tuberculosis.

June 2017. Publication. Jang, Jichan et al. “Efflux Attenuates the Antibacterial Activity of Q203 in Mycobacterium tuberculosis.” Antimicrobial Agents and Chemotherapy vol. 61,7 e02637-16. PMCID: PMC5487614